Long Acting, Sustainable Therapies for Opiate Addiction (R01)

Post Date

December 21st 2007

Application Due Date

January 7th 2011

Funding Opportunity Number

PAS-08-061

CFDA Number(s)

93.279

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.

Funding

• Estimated Total Funding:

  $4000000

• Award Range:

  $None - $None

Grant Description

-Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse, National Institutes of Health, encourages Research Project Grant (R01) applications from institutions/organizations that propose the development of sustained pharmacotherapies and behavioral treatments to reduce the risk of contraction and transmission of HIV. Specifically, this FOA supports applications directed at the development of (1) heroin/morphine-protein conjugates (heretofore referred to as heroin/morphine conjugate vaccines or HCVs) for the treatment of opiate addiction, (2) clinical systems for the application of currently available long-acting (30-day or longer sustained-release) dosage forms for opiate pharmacotherapies to optimize these sustained pharmacotherapies to effect the reduction of the risk for acquisition and transmission of HIV, and (3) effective clinical treatment modalities, including behavioral treatment in conjunction with pharmacotherapies, to improve the effectiveness of opiate treatment and reduce the risk behaviors associated with transmission of HIV. Clinical studies should include the assessment of HIV risk behaviors as an outcome measure. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. NIDA intends to commit initially a total of $4 million for FY 2008 to this Program Announcement to fund 6-8 meritorious applications that address the goals of this FOA. Set-aside funds for future years have not been determined. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/pa-files/PAS-08-061.html